Wockhardt's New Antibiotic Zaynich Targets $7-Billion US, Europe Market

Wockhardt Ltd. is eyeing a huge opportunity in the US and European markets with its new antibiotic, Zaynich. The company believes Zaynich could address a $7-billion market in these regions.

The pharmaceutical company recently finished a key meeting with the US Food and Drug Administration in May 2025, which is a step before officially submitting its application.

The company plans to file for USFDA approval in the second quarter of the current financial year, hoping to launch Zaynich in the US between April 2026 and March 2027. Wockhardt also aims to get approval for Zaynich in Europe and other growing markets in the second half of this financial year.

In India, Wockhardt has already applied for approval from the Drug Controller General of India and expects to launch Zaynich in the local market during the second half of the current fiscal year. This new antibiotic is designed to fight gram-negative infections and is projected to help 1.1 million patients in India alone.

Further, Wockhardt had reported a narrowing of their net loss. For the fourth quarter ended March 31, 2025, the company's net loss was Rs 45 crore, a significant improvement from the Rs 177-crore loss in the same period last year. Revenue also increased to Rs 743 crore from Rs 700 crore.

For the full financial year 2025, the net loss was Rs 57 crore, down from Rs 472 crore in the previous year, with revenue rising to Rs 3,012 crore from Rs 2,798 crore. Wockhardt's shares closed higher on Thursday, at Rs 1,528.60 on the BSE.

(With inputs from PTI)